LIB-01 appears to affect metabolic diseases and Dicot Pharma files new patent application
Uppsala, Sweden, June 6, 2024. The pharmaceutical company Dicot Pharma AB is developing LIB-01 into a new potency drug with improved properties compared to currently available drugs. New research results on LIB-01 show that the substance appears to influence factors linked to certain metabolic diseases. Based on these research results, the company has submitted a patent application for the treatment of several new indications.Dicot Pharma is developing the potency drug candidate LIB-01 with the aim of offering a treatment that surpasses current drugs, including a long-term effect on